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Personalized Medicine:  
A Perk of Privilege?
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advances in molecular testing and genomic technology offer 
promise in helping identify people at risk of developing disease 
and those most (or least) likely to benefit from risk reduction and 
treatment strategies. yet not all of those who are eligible for such 
technologies have access to the benefits of these advances. given 
the inequities in our health-care system, there is no assurance that 
expanding research into molecular and genomic testing will benefit 
everyone equally. moreover, widespread adoption of new and 
emerging technologies poses challenges for an already overtaxed 
health-care system.
Consider a 48-year-old premenopausal law 
professor who is diagnosed with a 2.2-cm 
breast cancer that is positive for hormone 
receptor and negative for human epider-
mal growth factor receptor-2, with grade 
2 histology. Because of a family history 
of early-onset breast cancer in a paternal 
aunt and her sister, she is advised to have 
genetic counseling and then testing for 
an inherited susceptibility to breast and 
ovarian cancer. She is found not to have 
a mutation in either BRCA1 or BRCA2. 
She undergoes a sentinel lymph node 
procedure that confirms the absence of 
lymph node involvement. Her oncolo-
gist recommends that, after approval has 
been secured from her insurance company, 
her primary tumor be sent for a 21-gene 
assay. This identifies the cancer as having 
a low risk score, indicating that chemo-
therapy will not improve the likelihood of 
disease-free and overall survival. She may 
have blood sent for CYP2D6 genotyping 
if her oncologist, who attends the annual 
meeting of the national oncology society, 
believes this will help predict the benefit of 
tamoxifen. She will most likely be treated 
with breast-conserving therapy, adjuvant 
radiation therapy, and tamoxifen. This 
patient has certainly benefited from what 
is commonly called personalized medicine, 
an emerging science that allows tailoring 
of treatment according to the characteris-
tics of host and disease.
Imagine now that, instead of having 
insurance through her employer, she has 
been laid off from a part-time job at a 
large retail store and has recently joined 
the ranks of the nearly 46 million unin-
sured Americans, or that she has Medic-
aid. She cannot pay for genetic counseling 
and testing. Concerned that she may have 
inherited a susceptibility to breast cancer, 
she elects to have bilateral mastectomy. 
Medicaid does not pay for the 21-gene 
assay in all but a handful of states, so she 
receives adjuvant chemotherapy followed 
by tamoxifen, CYP2D6 genotyping not 
even being considered by her oncologist. 
Based on her insurance status alone, she 
has not shared the benefits of advances in 
personalized medicine in the management 
of her disease.
The literature is replete with studies 
demonstrating health disparities among 
people of lower socioeconomic status 
(SES)—whether SES is measured accord-
ing to individual-level income and educa-
tion or by neighborhood socioeconomic 
variables. Although health disparities are 
due only in part to inequities in medical 
care, addressing the gaps in quality of care 
is obviously a worthwhile endeavor. It fol-
lows that correcting disparities in access to 
molecular and genomic technologies—an 
increasingly important aspect of medical 
care—will remedy, in part, disparities in 
the quality of care. Conversely, failing to 
do so will inevitably widen the differences 
between the haves and have-nots. The 
principle of distributive justice requires 
that the benefits of medical advances be 
shared equally by all people.1 As illus-
trated in the aforementioned case, access 
to molecular and genomic technologies 
varies according to insurance status, which 
in turn varies according to SES.
Lack of payment for molecular and 
genomic tests is only one barrier to full 
and equal access. Provider awareness 
and patient decision support are two 
other factors in determining who ben-
efits from application of new special-
ized tests. People with fewer economic 
resources are less likely to receive pre-
ventive services of all types, including 
risk reduction and screening services, 
and are less likely to have a usual source 
of medical care. Economic insecurity 
places competing demands on patients 
and their families, often leaving health 
care low on the list of priorities. Lower 
SES may also be associated with receipt 
of care from providers whose practices 
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people (and insurers) able and willing to 
pay for a test does not necessarily mean 
that they should.
Evaluating the impact of these tests 
across a broad range of outcomes—not 
only survival and cost-effectiveness but 
also patient satisfaction, quality of life, 
knowledge, decision regret, and other 
decision-making outcomes—is war-
ranted before we can know whether we 
can or should offer population-based 
testing approaches. It has been argued 
that improving the fidelity of established 
medical technologies—applying the 
right technology to the right people in 
the right way—will have a greater impact 
on the health of a population than will 
new technologies.4 That is, ensuring even 
distribution of “low-tech” biomarkers 
(for example, high-quality assessment of 
estrogen receptor status in primary breast 
cancers) may need to be our national 
priority over expanding access to newly 
discovered markers that have not yet 
found their proper place in prevention, 
diagnostic, and therapeutic algorithms. 
The collective behavior of our health-care 
system does not suggest any inclination to 
limit the use of expensive technologies.5 
Our reluctance (and perhaps inability) 
to withhold any technology from our 
patients who are able to pay makes it even 
more important that we scrutinize the use 
of new and old technologies—whether 
predictive, diagnostic, prognostic, or ther-
apeutic—along the entire continuum of 
prevention and medical care. As with new 
pharmaceutical agents, specific guidelines 
for the use of genomic technologies will 
increase their appropriate use; insurers 
can enforce compliance with guidelines 
by refusing to pay for technologies in 
patients or situations in which they have 
not proven to be effective. Strategic and 
comprehensive policies that address the 
optimal uptake of established tests while 
incorporating and identifying the correct 
use of emerging tests will increase the 
likelihood of credible, evidence-based 
delivery of care. Only in doing so will 
we reduce waste, reduce inequities, and 
achieve high-quality care for all.
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Obama, has the stated purpose “to secure 
the promise of personalized medicine for 
all Americans by expanding and acceler-
ating genomics research and initiatives 
to improve the accuracy of disease diag-
nosis, increase the safety of drugs, and 
identify novel treatments.” This bill, which 
may fare better under a new administra-
tion, reflects an emerging national dia-
logue that is beginning to address both 
access to and development of advances in 
medical technologies.
With political and scientific energy 
supporting the development and appli-
cation of such advances, are we to rush 
headlong toward expanded coverage of 
molecular and genomic technologies? 
How will we pay the costs of develop-
ment and deployment of what are expen-
sive tests? One could argue that the costs 
of caring for an individual patient may 
ultimately be lower when molecular and 
genomic technologies are incorporated 
into treatment decisions. From a societal 
standpoint, however, costs of medical care 
are likely to increase with expanded use 
of such technologies given the costs asso-
ciated with such technologies. Providing 
specialized information and decision 
support further increases the expenses 
associated with these tests.
Moreover, molecular and genomic 
technologies are often adopted with-
out rigorous evaluation3 or are used in 
settings or populations other than the 
ones for which they were intended. For 
example, despite conflicting data about 
the role of CYP2D6 polymorphisms and 
the lack of prospective data, insurance 
will generally cover the cost of CYP2D6 
genotyping. Expanding insurance cov-
erage of expensive tests will undoubt-
edly increase the demand for such tests 
among providers and patients even in 
cases of minimal or no benefit. Further-
more, direct-to-consumer marketing 
of genomic technologies will further 
increase demand for testing, as it has in 
the case of magnetic resonance imaging 
for breast cancer screening. Enthusiasm 
for new tests and technologies will, pre-
dictably, extend their use to people who 
fall outside the setting in which they 
were developed, increasing costs of care 
without corresponding improvements in 
health outcomes. Just because there are 
have fewer resources, such as access to 
certified genetic counselors or other 
forms of education and patient deci-
sion support. Clearly, improving pro-
vider knowledge and understanding 
of genomic medicine is a critical com-
ponent of any effort designed to effect 
change in care. Implementing educa-
tional programs for providers requires 
novel approaches for reaching practicing 
providers and those in training.
In addition, decision making about 
genetic testing and other molecular and 
genomic tests is far from simple. Under-
standing the concepts of probabilities, 
relative and absolute risk reduction, and 
short- and long-term consequences of 
testing or not testing does not come eas-
ily, even to medical providers. Health lit-
eracy and numeracy levels, low enough 
to present a barrier to informed decision 
making even among those with high levels 
of education, pose even greater barriers 
in people with lower levels of educational 
attainment.2 The stress associated with 
cancer and other serious illnesses is likely 
to further impede understanding and 
decision making. Decision aids, which 
can help elicit and clarify people’s prefer-
ences, may be particularly useful among 
the medically underserved. Development 
and dissemination of informational sup-
port, including decision aids, should thus 
be carried out in parallel with develop-
ment of novel molecular markers in order 
to help patients and their providers make 
the most of advances in molecular and 
genomic medicine.
Expanding access to molecular and 
genomic technologies to people of limited 
economic resources, including people in 
less wealthy countries, will allow more peo-
ple to benefit from scientific advances and 
may reduce the likelihood of overtreat-
ment, the risk of adverse drug reactions, 
and the costs of care for an individual 
patient. For example, in the first patient 
scenario, identifying the lack of benefit 
of chemotherapy given a low recurrence-
risk score, eliminated the use of chemo-
therapy, decreased the net costs of care, 
and improved the patient’s quality of life. 
The Genomics and Personalized Medicine 
Act of 2007 (S.976, available at http://www.
thomas.gov/cgi-bin/query/z?c110:S.976.
IS:), introduced by then-Senator Barack 
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Educating for  
Personalized Medicine:  
A Perspective From Oncology
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The personalized-medicine concept represents the future of oncology 
medicine. new genomics technologies will characterize patients 
biologically in ways that will drive more efficient and effective cancer 
treatment. yet the introduction of these technologies is disruptive 
to current practices in clinical oncology, as well as to current 
regulatory and reimbursement strategies. The efficient introduction 
of personalized medicine will require education in addition to 
behavioral and policy changes by the various involved stakeholders.
Personalized medicine:  
premise and promise
The concept of  an individualized 
approach to patient treatment is not new 
in medicine. Treatment decisions for 
individual patients have always involved 
an integration of complex clinicopatho-
logical, technical, and socioeconomic 
considerations, and nowhere is this more 
important than in treatment decision 
making for cancer. When the evidence is 
supporting, oncologists have long been 
willing to base treatment decisions on 
laboratory measurements of a patient’s 
tumor, the use of hormonal therapy in 
women with breast carcinoma being a 
decades-old example. The more recent 
premise of truly “personalized medicine,” 
however, extends much further. The new 
genomics technology increasingly allows 
the characterization in detail of the rel-
evant biology of an individual tumor and 
the patient with that tumor—potentially 
before, during, and after treatment. The 
clinical meaning of this biological char-
acterization will come most efficiently 
from the careful study of patients while 
they are being treated with targeted 
therapeutics in clinical trials. Tumor 
classifications will be radically revised 
to reflect clinically relevant biology; 
they will be linked more closely with 
biologically targeted therapeutics use 
and will therefore inform treatment 
decisions more effectively. It is entirely 
possible that the concept of tumor 
“classification”—at least for the purposes 
of treatment decision making—will 
evolve into one of tumor “characteriza-
tion” at the individual patient level.1
This new concept of personalized 
oncology medicine affects every stake-
holder in the cancer treatment com-
munity. How quickly the new biological 
information is transformed into better 
patient care and more efficient health-
care delivery will greatly depend on the 
education of these stakeholders regard-
ing the meaning and the implications of 
personalized medicine.
Educating for personalized medicine 
and overcoming the hurdles  
to its introduction
The challenges regarding the devel-
opment and introduction of the new 
genomic technologies and their potential 
for improvement of health care have been 
the focus of a number of recent activi-
ties and reports. The US Department of 
Health and Human Services (DHHS) Sec-
retary’s Advisory Committee on Genetics, 
Health, and Society (SACGHS) produced 
a report in May 2008 entitled “Realizing 
the Potential of Pharmacogenomics: 
Opportunities and Challenges” (http://
oba.od.nih.gov/oba/SACGHS/reports/
SACGHS_PGx_report.pdf).This report 
recognized the many challenges in inte-
grating pharmacogenomic information 
into the health-care and public health 
systems and made a series of recom-
mendations related in particular to the 
education and guidance of the multiple 
involved parties. Additionally, the Presi-
dent’s Council of Advisors on Science and 
Technology (PCAST) produced a report, 
“Priorities for Personalized Medicine,” in 
September 2008 (http://www.ostp.gov/
galleries/PCAST/pcast_report_v2.pdf). 
PCAST gathers advice from the private 
sector, including the academic commu-
nity and industry. In its study, PCAST 
examined eight major policy areas affect-
ing personalized medicine. Recommen-
dations were made only in the areas of 
technology/tools, regulation, and reim-
bursement. Particularly with respect to 
the issues of physician and patient edu-
cation and economics,  the report pointed 
out that policy recommendations have 
not been made because personalized-
medicine product development is still in 
early stages.
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